

# Ramaprasad Srinivasan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/666085/publications.pdf>

Version: 2024-02-01

40  
papers

2,257  
citations

516710

16  
h-index

330143

37  
g-index

40  
all docs

40  
docs citations

40  
times ranked

3947  
citing authors

#	ARTICLE	IF	CITATIONS
1	Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1540-1548.	7.0	21
2	Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	4
3	A challenging frontier – the genomics and therapeutics of nonclear cell renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2021, 33, 212-220.	2.4	6
4	<sup>18</sup> FFluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes. <i>Abdominal Radiology</i> , 2021, 46, 3301-3308.	2.1	4
5	Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 434-446.	2.8	10
6	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. <i>Cancer</i> , 2021, 127, 3957-3966.	4.1	11
7	Kidney cancer: from genes to therapy. <i>Current Problems in Cancer</i> , 2021, 45, 100773.	2.0	5
8	Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer. <i>Science Signaling</i> , 2021, 14, .	3.6	64
9	Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings. <i>Clinical Imaging</i> , 2020, 68, 14-19.	1.5	10
10	Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. <i>Journal of Clinical Oncology</i> , 2020, 38, 1146-1153.	1.6	39
11	Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 3596-3603.	2.5	17
12	Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery. <i>Current Opinion in Oncology</i> , 2020, 32, 240-249.	2.4	15
13	Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5004-5004.	1.6	53
14	Obstructive azoospermia secondary to bilateral epididymal cystadenomas in a patient with von Hippel-Lindau. <i>Urology Case Reports</i> , 2019, 27, 100922.	0.3	5
15	A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 6302-6308.	7.0	13
16	Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion. <i>BMC Cancer</i> , 2019, 19, 917.	2.6	12
17	The Metabolic Basis of Kidney Cancer. <i>Cancer Discovery</i> , 2019, 9, 1006-1021.	9.4	163
18	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	6.4	523

#	ARTICLE	IF	CITATIONS
19	Challenging and refining treatment paradigms. Nature Reviews Urology, 2018, 15, 77-78.	3.8	3
20	Comprehensive genomic and phenotypic characterization of germline <i>FH</i> deletion in hereditary leiomyomatosis and renal cell carcinoma. Genes Chromosomes and Cancer, 2017, 56, 484-492.	2.8	21
21	Determinants and prognostic implications of malignant ascites in metastatic papillary renal cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 114.e9-114.e14.	1.6	7
22	Recommendations for the Management of Rare Kidney Cancers. European Urology, 2017, 72, 974-983.	1.9	36
23	Predictors of mortality in metastatic papillary renal cell cancer.. Journal of Clinical Oncology, 2017, 35, 509-509.	1.6	1
24	SnapShot: Renal Cell Carcinoma. Cancer Cell, 2016, 29, 610-610.e1.	16.8	35
25	Therapeutic Strategies for Hereditary Kidney Cancer. Current Oncology Reports, 2016, 18, 50.	4.0	9
26	Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer. Cancer Research, 2016, 76, 2177-2185.	0.9	86
27	Metabolism and Oxidative Stress Response Pathways in Kidney Cancer: A Tale of Chance and Necessity. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 220-225.	3.8	4
28	New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease. Clinical Cancer Research, 2015, 21, 10-17.	7.0	88
29	Targeting ABL1-Mediated Oxidative Stress Adaptation in Fumarate Hydratase-Deficient Cancer. Cancer Cell, 2014, 26, 840-850.	16.8	87
30	Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nature Reviews Urology, 2014, 11, 465-475.	3.8	227
31	Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 4584-4584.	1.6	3
32	Clinical evaluation of 2-(18F) fluoro-2 deoxy-D-glucose PET/ CT in hereditary leiomyomatosis and renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 383-383.	1.6	3
33	The Glycolytic Shift in Fumarate-Hydratase-Deficient Kidney Cancer Lowers AMPK Levels, Increases Anabolic Propensities and Lowers Cellular Iron Levels. Cancer Cell, 2011, 20, 315-327.	16.8	190
34	UOK 262 cell line, fumarate hydratase deficient ( <i>FH</i> <sup>-/-</sup> / <i>FH</i> <sup>+/+</sup> ) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genetics and Cytogenetics, 2010, 196, 45-55.	1.0	131
35	Antiangiogenic therapy in renal cell carcinoma: from concept to reality. Nature Reviews Urology, 2007, 4, 74-75.	1.4	2
36	Hereditary Leiomyomatosis and Renal Cell Cancer: A Syndrome Associated With an Aggressive Form of Inherited Renal Cancer. Journal of Urology, 2007, 177, 2074-2080.	0.4	235

#	ARTICLE	IF	CITATIONS
37	Anti-angiogenic therapy in renal cell cancer. BJU International, 2007, 99, 1296-1300.	2.5	12
38	Nephrotic syndrome following non-myeloablative stem cell transplantation - Response to Ruiz-Arguelles and Gomez-Almaguer. British Journal of Haematology, 2006, 132, 802-803.	2.5	0
39	Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. British Journal of Haematology, 2006, 133, 305-314.	2.5	102
40	Hematopoietic Cell Transplantation for Renal Cell and other Solid Tumors. , 0, , 958-959.		0